Laura Gaetano

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications

Embedding Passive Monitoring Into Global Health and Longitudinal Patient Care.

Embedding Passive Monitoring Into Global Health and Longitudinal Patient Care.

Journal: JMIR formative research
Published: July 30, 2025

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: April 16, 2025

Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.

Presence of slowly expanding lesions in multiple sclerosis predicts progressive demyelination within lesions and normal-appearing tissue over time.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: February 14, 2025

Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study.

Somatosensory Profile of Central Post Stroke Pain of Thalamic Origin: Findings of a Quantitative Sensory Testing Study.

Journal: European journal of pain (London, England)
Published: December 22, 2024

AI-driven reclassification of multiple sclerosis progression.

AI-driven reclassification of multiple sclerosis progression.

Journal: Nature medicine
Published: October 29, 2024

Accelerating Parkinson's Disease drug development with federated learning approaches.

Accelerating Parkinson's Disease drug development with federated learning approaches.

Journal: NPJ Parkinson's disease
Published: August 08, 2024

Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus.

Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus.

Journal: Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
Published: October 07, 2023

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: May 06, 2023

Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging.

Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging.

Journal: European radiology
Published: April 20, 2023

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.

Journal: EBioMedicine
Published: March 09, 2023

Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.

Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis.

Journal: Journal of neurology
Published: June 20, 2022

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 08, 2022
Showing 1-12 of 46

Last Updated: 09/26/2026